Drug Profile
Research programme: liver X receptor agonists - Ralexar Therapeutics
Alternative Names: A 110Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Alexar Therapeutics
- Developer Ralexar Therapeutics
- Class
- Mechanism of Action Liver X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dermatitis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Dermatitis in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for research development in Dermatitis in USA (Topical)
- 02 Jan 2014 Early research in Dermatitis in USA (Parenteral)